AFM Completes Investigation into Exercising of Options by Crucell Management
01. April 2005 08:58 ET
|
Crucell N.V.
LEIDEN, Netherlands, April 1, 2005 (PRIMEZONE) -- The Netherlands Authority for the Financial Markets (AFM) has notified Crucell that its investigation into the exercise of options and the subsequent...
Crucell N.V.: Staf Van Reet to lead Galapagos Corporate Development
31. März 2005 05:06 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 31, 2005 (PRIMEZONE) -- Galapagos, a genomics-based drug discovery company, announces that it has appointed Staf Van Reet as VP Corporate Development. Dr. Van Reet will...
Crucell Announces PER.C6 Licensing Agreement with Vascular Biogenics
30. März 2005 01:31 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 30, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(R) research license agreement...
Crucell and DSM Announce PER.C6 Licensing Agreement with Mitsubishi Pharma for Protein Production
23. März 2005 02:06 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 23, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that DSM...
Crucell Signs Commercial PER.C6 License Agreement with SingVax for Vaccines against Japanese Encephalitis
22. März 2005 08:18 ET
|
Crucell N.V.
LEIDEN, Netherlands, March 22, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced the signing of a commercial PER.C6(R) license agreement with...
Crucell Secures Exclusive Patent License from NIH to Commercialize Ebola Vaccines
18. März 2005 02:07 ET
|
Crucell N.V.
LEIDEN, Netherlands, March 18, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has obtained an exclusive license to certain patents...
Crucell and NIH extend Ebola Vaccine Agreement
17. März 2005 02:07 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 17, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has extended its Cooperative Research and...
Crucell and DSM Announce PER.C6 Licensing Agreement with JCR Pharmaceuticals for Protein Production
10. März 2005 02:11 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 10, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they...
Crucell N.V.: Galapagos is Considering a Stock Exchange Listing
09. März 2005 03:36 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 9, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (Nasdaq:CRXL) announced today that Galapagos Genomics N.V. is considering a Euronext...
Galapagos Considering a Stock Exchange Listing
09. März 2005 03:18 ET
|
Crucell N.V.
LEIDEN, The Netherlands, March 9, 2005 (PRIMEZONE) -- Galapagos Genomics NV, a genomics-based drug discovery company, announces that it is considering a Euronext stock exchange listing in 2005. The...